DP与NP方案治疗复发转移乳腺癌临床观察  

The clinical study of docetaxel plus cisplatin versus vinorelbine plus cisplatin in the therapeutics of recurrent and/or metastatic breast cancers

作　　者：陈志敏[1] 戴秀梅[1] 王翔[1] 袁媛[1] 袁保兰[1] 

机构地区：[1]徐州市中心医院肿瘤内科,江苏徐州221009

出　　处：《徐州医学院学报》2008年第12期814-816,共3页Acta Academiae Medicinae Xuzhou

摘　　要：目的观察多西紫杉醇联合顺铂(DP方案)与诺维本联合顺铂(NP方案)治疗复发、转移乳腺癌的疗效及不良反应。方法58例乳腺癌患者随机分为2组进行治疗。DP方案28例:多西紫杉醇75 mg/m2,静脉输注,第1天;顺铂25 mg/m2,静脉输注,第2、3、4天。NP方案30例:诺维本25 mg/m2,静脉输注,第1、8天;顺铂用法同DP组。每21天为1个治疗周期。结果DP方案总有效率(57.1%)与NP方案总有效率(43.3%)差异无统计学意义(P>0.05);不良反应以胃肠道反应、骨髓抑制为主,经治疗后可耐受。结论DP方案与NP方案对复发、转移乳腺癌均有较好疗效,蒽环类药物治疗失败的患者可选用。Objective To evaluate the efficacy and adverse reactions of docetaxel plus cisplatin（DP） and vinorelbine plus cisplatin（NP） combinations in the therapeutics of the recurrence and metastasis of breast cancer.Methods 58 patients with breast cancer were divided into two groups at random.28 patients in group DP received intravenous dripping of docetaxel 75 mg/m^2 on the 1st day and cisplatin 25 mg/m^2 on the 2nd,3rd and 4th days.30 patients in group NP received intravenous dripping of vinorelbine 25 mg/m^2 on the 1st and 8th days and cisplatin 25 mg/m^2 on the 2nd,3rd and the 4th days.Both regimens were repeated every 3 weeks.Results The overall response rate for group DP was 57.1%（16/28）,and in group NP,the overall response rate was 43.3%（13/30）,there was no significant difference（P〉0.05）.The adverse reactions,which were mainly nausea /vomiting and myelosuppression,were tolerable after treatment.Conclusion Both DP and NP combined chemotherapy produced similar effects and are well tolerated in the patients with recurrent and/or metastatic breast cancer,and can serve as an alternative for failures with anthracyclines.

关 键 词：乳腺肿瘤 多西紫杉醇 顺铂 诺维本 化学疗法 转移 复发 

分 类 号：R737.9[医药卫生—肿瘤]